Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effektivitet och säkerhet hos paliperidonpalmitat vid schizofreni: en jämförelse med andra långverkande injicerbara antipsykotika
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2019 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesisAlternative title
Efficacy and safety of paliperidone palmitate in schizophrenia : a comparison with other long acting injectable antipsychotics (English)
Abstract [sv]

Schizofreni är en psykisk sjukdom som kännetecknas av hallucinationer, vanföreställningar och desorienterat tal. Incidensen är jämnt fördelad hos kvinnor och män och sjukdomen drabbar 15 per 100 000 individer. Negativa symtom innebär en förlust av kapaciteter, t.ex. motivationsbrist, afasi eller social isolering. Positiva symtom innebär vanföreställningar, hallucinationer och misstänksamhet. Dopaminhypotesen har länge varit den ledande teorin inom patofysiologi vid schizofreni. Även andra neurotransmittorer tros spela en viktig roll i sjukdomsutvecklingen. Första och andra generationens antipsykotika blockerar postsynaptiska dopaminerga receptorer och minskar därmed schizofrenisymtom. Antipsykotika i injektionsform är ett passande preparatval för patienter med en undermålig följsamhet till peroral antipsykotikabehandling. År 2009 registrerades paliperidonpalmitat, ett nytt andra generationens antipsykotika i injektionsform. Paliperidonpalmitat är en palmitatester av paliperidon (9-hydroxy-risperidon). Syftet med studien var att jämföra paliperidonpalmitat med andra antipsykotika i injektionsform vid schizofreni med avseende på effektivitet, tolerabilitet och biverkningsprofil. Fyra randomiserade kliniska studier samt en retrospektiv studie erhölls från artikelsökningar i databasen PubMed. Resultat från artikelanalyser visar likvärdiga antipsykotiska effekter hos paliperidonpalmitat, långverkande risperidoninjektion och haloperidoldekanoat. Paliperidonpalmitat och haloperidoldekanoat visades däremot ha olika biverkningsprofiler.

Abstract [en]

Schizophrenia is a mental disorder associated with symptoms such as hallucinations, delusions, disoriented speech and other mood disturbances. The prevalence is equally distributed among men and women and affect approximately 15 per 100 000 individuals. Negative schizophrenic symptoms are synonymous with loss of specific capacities such as lack of motivation, aphasia or social isolation. Positive symptoms include delusions, hallucinations and suspiciousness. Pathophysiology of schizophrenia is mostly due to deregulation of the neurotransmitter dopamine. Additional neurotransmitters are also believed to play an important role in the pathogenesis. First and second generations antipsychotics block postsynaptic dopaminergic receptors and consequently alleviate schizophrenic symptoms. Antipsychotic injections are a suitable administration form for patients with poor adherence to oral treatment. In 2009, paliperidone palmitate was registered as a new second-generation antipsychotic injection. Paliperidone palmitate is a palmitate ester of paliperidone, 9-hydroxyrisperidone. The aim of this study is to compare paliperidone palmitate with other injectable antipsychotics in schizophrenia focusing on efficacy, tolerability and side effects. A total of four randomized clinical trials and one retrospective study were derived from PubMed. Results from the trial analysis show equal antipsychotic effects for paliperidone palmitate, long-acting risperidone and haloperidol decanoate. On the other hand, paliperidone palmitate and haloperidol decanoate differ in their side effect profile.

Place, publisher, year, edition, pages
2019. , p. 39
Keywords [sv]
Paliperidonpalmitat, Schizofreni, Antipsykotika
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:lnu:diva-82636OAI: oai:DiVA.org:lnu-82636DiVA, id: diva2:1317147
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2019-05-24 Created: 2019-05-21 Last updated: 2019-05-24Bibliographically approved

Open Access in DiVA

fulltext(758 kB)15 downloads
File information
File name FULLTEXT01.pdfFile size 758 kBChecksum SHA-512
9b23d6d1a8256b89869fc6323cd11d5fd8a3393bf23ed58a51777bb0caabeb92b07acc1cee0cc3f443dda1422609215484075dba16e4efa602c10f08dbee8812
Type fulltextMimetype application/pdf

By organisation
Department of Chemistry and Biomedical Sciences
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 15 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 108 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf